Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis
Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis SHANGHAI, May 13, 2021 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced the first patient has been dosed in their Phase III, global clinical trial (RSJ10333) of SHR0302, a potent and highly selective small molecule inhibitor of Janus kinase type 1 (JAK1) in patients with moderate-to-severe Atopic Dermatitis (AD). The trial is being conducted in Canada and Ch...
Source: finanznachrichten.de